BillionToOne Company
BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to makepre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting with developing countries.
Investors
(Reupload).png)
Technology:
BioTech
Industry:
Pregnancy & Nursing
Headquarters:
Menlo Park, California, United States
Founded Date:
01-01-2016
Employees Number:
101-250
Funding Status:
Late Stage Venture
Investors Number:
23
Total Funding:
$212,400,000
Estimated Revenue:
$10M to $50M
Last Funding Date:
Mar 30, 2022
Last Funding Type:
Series C
Register and Claim Ownership